Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in an article titled “FDA’s Biggest New Policies of 2014: Midyear Report.” (Read the full version – subscription required.)
Following is an excerpt:
New rules and guidance from the U.S. Food and Drug Administration have made lots of waves with drug and device makers in 2014, sparking debate about future oversight of off-label promotion, social media interactions and the rapidly evolving field of clinical software.
However, even describing a single potential side effect will consume valuable characters, and for products with multiple serious risks or contraindications, it’s widely believed that tweeting in accordance with the FDA’s rules will prove impossible.
“It’s going to be very rare for someone to use Twitter to talk about product-specific information,” said Bradley Merrill Thompson of Epstein Becker Green.